In 2004, Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) because of an increased risk of heart attack and stroke. In December 2004, the FDA announced a ﾓblack boxﾔ warning for valdecoxib (Bextra), stating that its use in patients undergoing coronary artery bypass graft surgery is contraindicated.